.jpg)
STAT Plus: Pfizer’s top-selling vaccine won’t prevent Covid-19, but could get a boost because of it
Vaccines tend to get a bad reputation among biotech investors. Which makes it easy to forget that Pfizer’s top-selling product, with $5.8 billion in annual sales, is a vaccine: Prevnar 13.
Now Prevnar may be seeing a boost because of worries about the novel coronavirus, according to Umer Raffat, an analyst at Evercore ISI, an investment bank.
